These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 34031051)

  • 1. Safety, Tolerability, and Population Pharmacokinetics of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients.
    Arrieta AC; Neely M; Day JC; Rheingold SR; Sue PK; Muller WJ; Danziger-Isakov LA; Chu J; Yildirim I; McComsey GA; Frangoul HA; Chen TK; Statler VA; Steinbach WJ; Yin DE; Hamed K; Jones ME; Lademacher C; Desai A; Micklus K; Phillips DL; Kovanda LL; Walsh TJ
    Antimicrob Agents Chemother; 2021 Jul; 65(8):e0029021. PubMed ID: 34031051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi.
    Desai A; Kovanda L; Kowalski D; Lu Q; Townsend R; Bonate PL
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5483-91. PubMed ID: 27381396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole.
    Kovanda LL; Marty FM; Maertens J; Desai AV; Lademacher C; Engelhardt M; Lu Q; Hope WW
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28289034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Isavuconazonium Sulfate in Healthy Adult Japanese Subjects.
    Shirae S; Ose A; Kumagai Y
    Clin Pharmacol Drug Dev; 2022 Jun; 11(6):744-753. PubMed ID: 35191210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi.
    Desai AV; Kovanda LL; Hope WW; Andes D; Mouton JW; Kowalski DL; Townsend RW; Mujais S; Bonate PL
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue Distribution and Elimination of Isavuconazole following Single and Repeat Oral-Dose Administration of Isavuconazonium Sulfate to Rats.
    Schmitt-Hoffmann AH; Kato K; Townsend R; Potchoiba MJ; Hope WW; Andes D; Spickermann J; Schneidkraut MJ
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28971866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study).
    Kovanda LL; Desai AV; Lu Q; Townsend RW; Akhtar S; Bonate P; Hope WW
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4568-76. PubMed ID: 27185799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.
    Maertens JA; Raad II; Marr KA; Patterson TF; Kontoyiannis DP; Cornely OA; Bow EJ; Rahav G; Neofytos D; Aoun M; Baddley JW; Giladi M; Heinz WJ; Herbrecht R; Hope W; Karthaus M; Lee DG; Lortholary O; Morrison VA; Oren I; Selleslag D; Shoham S; Thompson GR; Lee M; Maher RM; Schmitt-Hoffmann AH; Zeiher B; Ullmann AJ
    Lancet; 2016 Feb; 387(10020):760-9. PubMed ID: 26684607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isavuconazonium sulfate: a triazole prodrug for invasive fungal infections.
    Murrell D; Bossaer JB; Carico R; Harirforoosh S; Cluck D
    Int J Pharm Pract; 2017 Feb; 25(1):18-30. PubMed ID: 27569742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population Pharmacokinetics, Exposure-Safety, and Probability of Target Attainment Analyses for Isavuconazole in Japanese Patients With Deep-Seated Mycoses.
    Shirae S; Tsuruya Y; Kozaki T; Mizuhata J; Ose A
    J Clin Pharmacol; 2023 Jun; 63(6):704-714. PubMed ID: 36781411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population Pharmacokinetics of Intravenous Isavuconazole in Solid-Organ Transplant Recipients.
    Wu X; Venkataramanan R; Rivosecchi RM; Tang C; Marini RV; Shields RK; Clancy CJ; Nguyen MH
    Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31767725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A non-randomized trial to assess the safety, tolerability, and pharmacokinetics of posaconazole oral suspension in immunocompromised children with neutropenia.
    Arrieta AC; Sung L; Bradley JS; Zwaan CM; Gates D; Waskin H; Carmelitano P; Groll AH; Lehrnbecher T; Mangin E; Joshi A; Kartsonis NA; Walsh TJ; Paschke A
    PLoS One; 2019; 14(3):e0212837. PubMed ID: 30913226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population Pharmacokinetics of Posaconazole in Immune-Compromised Children and Assessment of Target Attainment in Invasive Fungal Disease.
    McCann S; Sinha J; Wilson WS; McKinzie CJ; Garner LM; Gonzalez D
    Clin Pharmacokinet; 2023 Jul; 62(7):997-1009. PubMed ID: 37179512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Pharmacokinetic Bioequivalence Study Comparing Different-Strength and -Size Capsules of Isavuconazonium Sulfate in Healthy Japanese Subjects.
    Shirae S; Mori Y; Kozaki T; Ose A; Hasegawa S
    Clin Pharmacol Drug Dev; 2022 Sep; 11(9):1092-1098. PubMed ID: 35403832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isavuconazonium sulfate for the treatment of fungal infection.
    Walker RC; Zeuli JD; Temesgen Z
    Drugs Today (Barc); 2016 Jan; 52(1):7-16. PubMed ID: 26937491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and Bioequivalence of Isavuconazole Administered as Isavuconazonium Sulfate Intravenous Solution via Nasogastric Tube or Orally in Healthy Subjects.
    Desai A; Helmick M; Heo N; Moy S; Stanhope S; Goldwater R; Martin N
    Antimicrob Agents Chemother; 2021 Aug; 65(9):e0044221. PubMed ID: 34181478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of isavuconazonium sulfate and its active metabolite isavuconazole in healthy dogs.
    McQuinn E; Mochel JP; Borts D; Hanzlicek AS; Allenspach K; Palerme JS
    PLoS One; 2024; 19(7):e0305766. PubMed ID: 39012876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isavuconazonium sulfate: a new agent for the treatment of invasive aspergillosis and invasive mucormycosis.
    Kovanda LL; Maher R; Hope WW
    Expert Rev Clin Pharmacol; 2016 Jul; 9(7):887-97. PubMed ID: 27160418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isavuconazole absorption following oral administration in healthy subjects is comparable to intravenous dosing, and is not affected by food, or drugs that alter stomach pH.
    Schmitt-Hoffmann A; Desai A; Kowalski D; Pearlman H; Yamazaki T; Townsend R
    Int J Clin Pharmacol Ther; 2016 Aug; 54(8):572-80. PubMed ID: 27345284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two Phase 1, Open-Label, Mass Balance Studies to Determine the Pharmacokinetics of
    Townsend R; Kato K; Hale C; Kowalski D; Lademacher C; Yamazaki T; Akhtar S; Desai A
    Clin Pharmacol Drug Dev; 2018 Feb; 7(2):207-216. PubMed ID: 28750160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.